Development and operation of the defence COVID-19 lab as a SARS-CoV-2 diagnostic screening capability for UK military personnel
-
Published:2022-07-25
Issue:
Volume:
Page:e002134
-
ISSN:2633-3767
-
Container-title:BMJ Military Health
-
language:en
-
Short-container-title:BMJ Mil Health
Author:
Weller Simon AORCID, Armstrong S R, Bailey S, Burnell H T, Burt E L, Cant N E, Cawthorne K R, Chester M, Choules J E, Coe N AORCID, Coward L, Cox V L, Emery E R, Evans C P, Finn A, Halford C M, Hamblin K A, Harrison G V, Hartley M G, Hudson C, James B, Jones H E, Keyser E, Lonsdale C L, Marshall L E, Maule C E, Miles J A, Newstead S L, Nicholls M, Osborne C, Pearcy A S, Penny L D, Perrot R, Rachwal P, Robinson V, Rushton D, Stahl F M, Staplehurst S V, Stapleton H L, Steeds K, Stephenson K, Thompson I J, Thwaite J E, Ulaeto D O, Waters N, Wills D J, Wills Z S, Rees C, Hutley E J
Abstract
BackgroundIn the face of the COVID-19 pandemic, the Defence Science and Technology Laboratory (Dstl) and Defence Pathology combined to form the Defence Clinical Lab (DCL), an accredited (ISO/IEC 17025:2017) high-throughput SARS-CoV-2 PCR screening capability for military personnel.Laboratory structure and resourceThe DCL was modular in organisation, with laboratory modules and supporting functions combining to provide the accredited SARS-CoV-2 (envelope (E)-gene) PCR assay. The DCL was resourced by Dstl scientists and military clinicians and biomedical scientists.Laboratory resultsOver 12 months of operation, the DCL was open on 289 days and tested over 72 000 samples. Six hundred military SARS-CoV-2-positive results were reported with a median E-gene quantitation cycle (Cq) value of 30.44. The lowest Cq value for a positive result observed was 11.20. Only 64 samples (0.09%) were voided due to assay inhibition after processing started.ConclusionsThrough a sustained effort and despite various operational issues, the collaboration between Dstl scientific expertise and Defence Pathology clinical expertise provided the UK military with an accredited high-throughput SARS-CoV-2 PCR test capability at the height of the COVID-19 pandemic. The DCL helped facilitate military training and operational deployments contributing to the maintenance of UK military capability. In offering a bespoke capability, including features such as testing samples in unit batches and oversight by military consultant microbiologists, the DCL provided additional benefits to the UK Ministry of Defence that were potentially not available from other SARS-CoV-2 PCR laboratories. The links between Dstl and Defence Pathology have also been strengthened, benefitting future research activities and operational responses.
Funder
Department of Health and Social Care
Reference13 articles.
1. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2;Nat Microbiol,2020 2. A new coronavirus associated with human respiratory disease in China 3. World Health Organization . Laboratory biosafety guidance related to coronavirus disease (COVID-19). WHO/WPE/GIH/2020.3. Available: https://www.who.int/publications/i/item/laboratory-biosafety-guidance-related-to-coronavirus-disease-(covid-19) [Accessed Mar 2020]. 4. Public Health England . COVID-19: guidance for sampling and for diagnostic laboratories. Available: https://wwwgovuk/government/publications/wuhan-novel-coronavirus-guidance-for-clinical-diagnostic-laboratories [Accessed Mar 2020]. 5. Bailey D , Shallcross J , H. Logue C , et al . Development and operation of Ebola diagnostic laboratories led by public health England in Sierra Leone during the West African Ebola outbreak 2013-2015. Clin Microbiol Infect Dis 2016;1.doi:10.15761/CMID.1000S1004
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|